Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

46P - Multi-center, phase II study of docetaxel (DTX) plus ramucirumab (RAM) following platinum-based chemotherapy plus ICIs in patients with NSCLC: SCORPION study


31 Mar 2023


Poster Display session


Reiko Matsuzawa


Journal of Thoracic Oncology (2023) 18 (4S): S35-S88.


R. Matsuzawa1, M. Morise2, K. Ito3, O. Hataji3, K. Takahashi4, Y. Kuwatsuka5, Y. Goto6, K. Imaizumi6, H. Itani7, T. Yamaguchi8, Y. Zenke9, M. Oki10, M. Ishii2

Author affiliations

  • 1 Nagoya/JP
  • 2 Nagoya University Graduate School of Medicine, Nagoya/JP
  • 3 Matsusaka Municipal Hospital, Matsusaka/JP
  • 4 Anjo Kosei Hospital, Anjo/JP
  • 5 Nagoya University Hospital, Nagoya/JP
  • 6 Fujita Health University School of Medicine, Toyoake/JP
  • 7 Ise Red Cross Hospital, Ise/JP
  • 8 Aichi Cancer Center Hospital, Nagoya/JP
  • 9 National Cancer Center Hospital East, Kashiwa/JP
  • 10 National Hospital Organization Nagoya Medical Center, Nagoya/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 46P


Platinum-based chemotherapy plus immune check point inhibitors (ICIs) have become a front-line standard treatment in NSCLC, but no prospective data of DTX plus RAM following front-line chemotherapy plus ICIs are available. Previous research has proven residual ICIs efficacy beyond 20 weeks after termination of ICIs, and VEGF-R2 blockade could enhance antitumor immunity by improving T-cell function. Here, we report the results of multicenter, phase II study of DTX plus RAM following front-line chemotherapy plus ICIs.


The primary end point of the study was objective response rate (ORR), and secondary endpoints were disease control rate (DCR), progression-free survival (PFS), and safety etc. Patients were treated with 60 mg/m2 of DTX and 10 mg/kg of RAM on day 1 with strong recommendation of pegfilgrastim on day 2 every 3 weeks. A null and alternative hypothesis of ORR were set as 10% and 30% with α error of 0.1 and β error of 0.1.


Thirty-three patients were recruited from 8 institutions. Patient characteristics were as follows: median age (range): 66 (42–79) y; ECOG-PS 1, n = 13 (39%); interval after last administration of ICIs<6 weeks, n = 21 (64%). In the efficacy analysis population (n = 32), the primary endpoint was met as 11 patients achieved PR with ORR at 34.4% (80%CI, 23.1–47.2%). Another 15 patients achieved SD and the DCR was 81.3% (95%CI, 63.6–92.8%). Median PFS was 6.5 months. Grade≥3 anemia and febrile neutropenia was observed in 2 (6%) and 3 patients (9%). No treatment-related deaths and no new safety signals were observed.


DTX plus RAM demonstrated encouraging antitumor activity with a manageable safety profile in patients who have failed with front-line chemotherapy plus ICIs.

Clinical trial identification


Legal entity responsible for the study

M. Morise.


Eli Lilly.


M. Morise: Financial Interests, Institutional, Research Grant: Eli Lilly, Boehringer Ingelheim; Financial Interests, Institutional, Principal Investigator: Roche, Chugai, AstraZeneca, Taiho, Merck Serono, AbbVie, Ono. K. Ito: Financial Interests, Personal, Invited Speaker: Eli Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.